Lee Tae Yoon, Petkau John, Saatchi Ariana, Marra Fawziah, Turvey Stuart E, Lishman Hannah, Patrick David M, Cragg Jacquelyn J, Johnson Kate M, Sadatsafavi Mohsen
Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Front Allergy. 2024 Dec 23;5:1491985. doi: 10.3389/falgy.2024.1491985. eCollection 2024.
Infant antibiotic use is associated with increased risk of asthma. We examined the population impact of antibiotic exposure in the first year of life on the burden of pediatric asthma in British Columbia, Canada, using simulation modeling.
We performed a Bayesian meta-analysis of empirical studies to construct dose-response equations between antibiotic exposure in the first year of life and pediatric (<19 years of age) asthma. We used administrative health data to document trends in infant (<1 year of age) antibiotic use in British Columbia during 2001 and 2018 (the study period). An independently developed microsimulation model of asthma was utilized to estimate asthma-related outcomes under three scenarios pertaining to the trends in antibiotic use during the study period: (1) observed trends, (2) flat trend in which the prescription rate remained at the 2001 value, and (3) intermediate trends midway between these two. We reported cumulative person-years with asthma, cumulative asthma incidence, and cumulative asthma exacerbations among the pediatric population during the study period.
There were 773,160 live births during the study period, with an average antibiotic prescription rate of 523 per 1,000 infants in the first year of life. The prescription rate decreased by 71.5% during the study period. In Scenario 1, there were 1,982,861 person-years with asthma, 183,392 asthma incident cases, and 383,072 exacerbations. Had the antibiotic exposure remained at the 2001 values (Scenario 2), there would have been additional 37,213 person-years with asthma, 10,053 asthma incident cases, and 23,280 exacerbations. Had the decline been half of the observed trend (Scenario 3), there would have been additional 20,318 person-years with asthma, 5,486 asthma incident cases, and 12,728 exacerbations. At least 80% of the excess burden in each outcome was attributable to the younger pediatric population of <10 years of age.
The decline in infant antibiotic exposure has resulted in a substantial reduction in the burden of asthma in British Columbia. Such benefits should be considered when evaluating the value proposition of initiatives aimed at reducing unnecessary antibiotic exposure in early life.
婴儿使用抗生素与哮喘风险增加有关。我们使用模拟模型研究了加拿大不列颠哥伦比亚省1岁以内婴儿接触抗生素对儿童哮喘负担的人群影响。
我们对实证研究进行了贝叶斯荟萃分析,以构建1岁以内婴儿抗生素接触与儿童(<19岁)哮喘之间的剂量反应方程。我们使用行政健康数据记录了2001年至2018年(研究期间)不列颠哥伦比亚省婴儿(<1岁)抗生素使用趋势。利用一个独立开发的哮喘微观模拟模型,在与研究期间抗生素使用趋势相关的三种情景下估计哮喘相关结局:(1)观察到的趋势,(2)处方率保持在2001年水平的平稳趋势,以及(3)介于这两者之间的中间趋势。我们报告了研究期间儿童人群中哮喘的累积人年数、累积哮喘发病率和累积哮喘加重次数。
研究期间有773,160例活产婴儿,1岁以内婴儿的平均抗生素处方率为每1000名婴儿523例。研究期间处方率下降了71.5%。在情景1中,有1,982,861人年患哮喘,183,392例哮喘新发病例,383,072次加重。如果抗生素接触保持在2001年的水平(情景2),将额外有37,213人年患哮喘,10,053例哮喘新发病例,23,280次加重。如果下降幅度为观察到的趋势的一半(情景3),将额外有20,318人年患哮喘,5,486例哮喘新发病例,12,728次加重。每个结局中至少80%的额外负担归因于10岁以下的儿童人群。
婴儿抗生素接触的减少导致不列颠哥伦比亚省哮喘负担大幅降低。在评估旨在减少生命早期不必要抗生素接触的举措的价值主张时,应考虑到这些益处。